Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: ModernaTX, Inc.
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
This description comes directly from the study's public registry record.
Moderna WeCare Team · +1-866-663-3762 · WeCareClinicalTrials@modernatx.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Mass General Brigham | Boston, Massachusetts, United States | Recruiting |
| Tisch Cancer Institute at Mount Sinai | New York, New York, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Recruiting |
| Atrium Health Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Penn Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| The Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07116616